Patient P-01872

Synthetic patientNBL-101 · Day 104 · 45–54 · M · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

91%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −14% vs expected — Dietary Support Protocol NP-02
Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 48 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 48.

Primary contributors, last 14 days

Inflammatory activity-6
Treatment adherence+3

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −14%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 53
- WearableHRV 23 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 35/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 64 and rising
- WearableSleep 5.6 h, below personal baseline
Autonomic recovery ↑45
- WearableResting HR 75 bpm
- WearableShort sleep window
Drug metabolism and exposure ↑20
- BloodToxicity index 46

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 35/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 20 ms
Sleep: 5.8 h
Steps: 5,555
Resting HR: 74 bpm

Daily log: GI score 64, nutritional resilience 34, adherence 50.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01409	63%	S14	SC-12	improved	41
P-01462	63%	S14	NP-02	improved	47
P-01692	59%	S14	NP-02	improved	49
P-01865	59%	S14	NP-02	no change	51
P-01332	58%	S14	NP-02	improved	43
P-01834	56%	S14	NP-02	improved	44
P-01496	54%	S14	SC-12	improved	46
P-01393	53%	S14	GI-04	improved	53
P-01573	53%	S14	GI-04	improved	49
P-01775	53%	S14	SC-12	improved	48
P-01595	52%	S14	GI-04	no change	51
P-01656	52%	S14	ME-01	improved	41